A phase II study of Foretinib (an oral multi-kinase inhibitor of MET, RON, AXL, TIE-2, and VEGF receptors) in patients with triple-negative breast cancer observed a clinical benefit rate of 46 %. Here, MET is linked to triple-negative breast carcinoma.